Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  The Oncologist

• Publication date

  2017-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1634/theoncologist.2016-0443PMID 28533476PMCID PMC5469587
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer

  2017cited by this paper
• Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

  2016cited by this paper
• Prognostic Significance of Preoperative Neutrophil–Lymphocyte Ratios in Patients with Stage I Non-small Cell Lung Cancer After Complete Resection

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients

  2015cited by this paper
• The association between the neutrophil-to-lymphocyte ratio and mortality in critical illness: an observational cohort study

  2015cited by this paper
• Clinical significance of preoperative neutrophil-lymphocyte vs platelet-lymphocyte ratio in primary operable patients with non-small cell lung cancer.

  2015cited by this paper
• Perioperative neutrophil:lymphocyte ratio and postoperative NSAID use as predictors of survival after lung cancer surgery: a retrospective study

  2015cited by this paper
• The Role of the Mediators of Inflammation in Cancer Development

  2015cited by this paper
• Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis

  2015influential reference
• Blood Neutrophil–Lymphocyte Ratio Predicts Survival in Patients with Advanced Pancreatic Cancer Treated with Chemotherapy

  2014cited by this paper
• The Effect of Radiation on the Immune Response to Cancers

  2014cited by this paper
• Interactions between neutrophils and non-small cell lung cancer cells: enhancement of tumor proliferation and inflammatory mediator synthesis

  2014cited by this paper
• Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis.

  2014cited by this paper
• Association of pretreatment neutrophil‐to‐lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration‐resistant prostate cancer (mCRPC) treated with first‐line docetaxel

  2014cited by this paper
• Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review

  2013cited by this paper
• Neutrophil:Lymphocyte Ratio and Intraoperative Use of Ketorolac or Diclofenac are Prognostic Factors in Different Cohorts of Patients Undergoing Breast, Lung, and Kidney Cancer Surgery

  2013cited by this paper
• Usefulness of Pretreatment Neutrophil to Lymphocyte Ratio in Predicting Disease-Specific Survival in Breast Cancer Patients

  2013cited by this paper
• Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer

  2012cited by this paper
• The Role of Tumor-Infiltrating Immune Cells and Chronic Inflammation at the Tumor Site on Cancer Development, Progression, and Prognosis: Emphasis on Non-small Cell Lung Cancer

  2011cited by this paper
• The role of myeloid cells in the promotion of tumour angiogenesis

  2008cited by this paper
• Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non–Small Cell Lung Cancer

  2008cited by this paper
• Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

  2008cited by this paper
• Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma

  2006cited by this paper
• Inflammation and cancer

  2002cited by this paper
• [Inflammation and cancer].

  1974cited by this paper

• Immune-inflammatory predictors of early and brain recurrence in young patients with resected non-small cell lung cancer.

  2026cites this paper
• A long-term survival prediction model for non-small cell lung cancer based on blood inflammatory biomarkers

  2026cites this paper
• Effective dose to immune cells combined with platelet-to-lymphocyte ratio predicts lymphopenia and prognosis in unresectable locally advanced non-small cell lung cancer

  2025cites this paper
• The value of peripheral blood inflammation markers in risk assessment and prediction of lung cancer

  2025cites this paper
• Clinical and nutritional-inflammatory biomarkers-based nomogram predicts survival in recurrent or metastatic cervical cancer treated with immune checkpoint inhibitors

  2025cites this paper
• Combined effects of nutrition, inflammatory status, and sleep quality on mortality in cancer survivors

  2024cites this paper
• Comparison of Prognostic Values of Seven Immune Indexes in Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab: How Effective Can They Be Regarding Our Treatment Decisions?

  2024cites this paper
• Lung immune prognostic index (LIPI) as a prognostic factor in patients with extensive-stage small cell lung cancer treated with first-line chemoimmunotherapy

  2024cites this paper
• Prognostic value of neutrophil-to-lymphocyte ratio change in patients with locally advanced non-small cell lung cancer treated with thoracic radiotherapy

  2024cites this paper
• Geriatric nutritional risk index and controller nutritional status score before metastatic first-line chemotherapy predict survival in patients over 70 years of age with metastatic bladder cancer

  2024cites this paper
• Clinical significance of the advanced lung cancer inflammation index in patients with limited-stage small cell lung cancer treated with chemoradiotherapy

  2024cites this paper
• Preoperative Exercise Training Decreases Complications of Minimally Invasive Lung Cancer Surgery- A Randomized Controlled Trial.

  2024cites this paper
• Current and Emerging Diagnostic, Prognostic, and Predictive Biomarkers in Head and Neck Cancer

  2024cites this paper
• Systemic inflammatory indices as a non-invasive grading modality for endometriosis: a comparative study versus exploratory laparoscopy

  2024cites this paper
• Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients Treated with Definitive Chemoradiotherapy for Locally Advanced Oesophageal Squamous Cell Carcinoma

  2023cites this paper
• Variation in infant rhesus monkeys' (Macaca mulatta) neutrophil-to-lymphocyte ratio is associated with environmental conditions, emotionality, and cortisol concentrations, and predicts disease-related outcomes.

  2023cites this paper
• Controlling Nutritional Status (CONUT) score is a prognostic marker in III-IV NSCLC patients receiving first-line chemotherapy

  2023cites this paper
• Prognostic Markers in Operated Non-Small Cell Lung Cancer Patients

  2023cites this paper
• Dosiomics and radiomics improve the prediction of post-radiotherapy neutrophil-lymphocyte ratio in locally advanced non-small cell lung cancer.

  2023cites this paper
• Significance of neutrophil to lymphocyte ratio as a predictor of outcome in head and neck cancer treated with definitive chemoradiation

  2023cites this paper
• Prognostic and clinicopathological impacts of systemic immune-inflammation index on patients with diffuse large B-cell lymphoma: a meta-analysis

  2023cites this paper
• Low neutrophil-to-lymphocyte ratio predicts overall survival benefit in advanced NSCLC patients with low PD-L1 expression and receiving chemoimmunotherapy

  2023influential citation
• CANCER-ASSOCIATED ADIPOCYTES AND PROGNOSTIC VALUE OF PREOPERATIVE NEUTROPHIL-LYMPHOCYTE RATIO IN GASTRIC CANCER.

  2023cites this paper
• Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in non-small cell lung cancer

  2023cites this paper
• Serum cytokine analysis in a cohort of advanced non-small cell lung cancer treated with PD-1 inhibitors reveals predictive markers of CXCL12

  2023influential citation
• Prognostic Value of Systemic Immune-Inflammation Index-Based Nomogram in Patients with Extrahepatic Cholangiocarcinoma Treated by Percutaneous Transhepatic Biliary Stenting Combined with 125I Seed Intracavitary Irradiation

  2023cites this paper
• Evaluation and modifcation of lung immune prognostic index in patients with metastatic NSCLC treated by immunotherapy

  2023cites this paper
• Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer

  2023cites this paper
• Combined systemic immune-inflammatory index and prognostic nutritional index predict outcomes in advanced non-small cell lung cancer patients receiving platinum-doublet chemotherapy

  2023cites this paper
• Emerging viral infections in immunocompromised patients: A great challenge to better define the role of immune response

  2023cites this paper
• NOVEL INFLAMMATORY PROGNOSTIC MARKERS IN LUNG CANCER PATIENTS TREATED WITH DEFINITIVE CHEMORADIOTHERAPY

  2022cites this paper
• Disparities in inflammation between non-Hispanic black and white individuals with lung cancer in the Greater Chicago Metropolitan area

  2022cites this paper
• Prognostic and Clinical Value of the Systemic Immune-Inflammation Index in Biliary Tract Cancer: A Meta-Analysis

  2022cites this paper
• Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy

  2022cites this paper
• Neutrophil–lymphocyte ratio as a predictor of adverse outcome in patients with community‐acquired pneumonia: A systematic review

  2022cites this paper
• Pretreatment Neutrophil-to-Lymphocyte Ratio and Smoking History as Prognostic Factors in Advanced Non–Small Cell Lung Cancer Patients Treated with Osimertinib

  2022cites this paper
• Neutrophil-Lymphocyte Ratio (NLR) and Platelet-Lymphocyte Ratio (PLR) as neuroinflammatory biomarkers in Amyotrophic Lateral Sclerosis (ALS) progression

  2022cites this paper
• Identifying Early Predictive Markers for Immune-Related Adverse Events in Nivolumab-Treated Patients with Renal Cell Carcinoma and Gastric Cancer

  2022cites this paper
• Lymphocyte percentage as a valuable predictor of prognosis in lung cancer

  2022cites this paper
• Frontiers in Pharmacology: Review Manuscript Targeting of the Neutrophil as an Adjunctive Strategy in Non-Small Cell Lung Cancer

  2021cites this paper
• A Validation Study on the Lung Immune Prognostic Index for Prognostic Value in Patients with Locally Advanced Non-Small Cell Lung Cancer.

  2021cites this paper
• Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy.

  2021cites this paper
• Neutrophil to lymphocyte ratio influences impact of steroids on efficacy of immune checkpoint inhibitors in lung cancer brain metastases

  2021cites this paper
• Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer

  2021cites this paper
• Hypofractionated Radiotherapy for Locally or Systemically Advanced Non-small Cell Lung Cancer

  2021cites this paper
• Systemic Immune-In ammation Index is a Promising Noninvasive Biomarker for Predicting the Survival of Urinary System Cancers: A Systematic Review and Meta-Analysis

  2021cites this paper
• Impact of neutrophil-to-lymphocyte ratio throughout the course of chemoradiotherapy on overall survival and distant failure in unresectable stage III non-small cell lung cancer

  2021cites this paper
• Evaluation of the Lung Immune Prognostic Index in Non-Small Cell Lung Cancer Patients Treated With Systemic Therapy: A Retrospective Study and Meta-Analysis

  2021cites this paper
• Neutrophil-to-lymphocyte ratio in sporadic amyotrophic lateral sclerosis

  2021cites this paper
• Predicting if lung cancer will relapse-The role of neutrophil/lymphocyte ratio.

  2021cites this paper
• The Addition of Peripheral Blood Inflammatory Indexes to Nomogram Improves the Predictive Accuracy of Survival in Limited-Stage Small Cell Lung Cancer Patients

  2021cites this paper
• Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non‐small‐cell lung cancer treated with chemoradiotherapy

  2021cites this paper
• Systemic immune-inflammation index is a promising non-invasive biomarker for predicting the survival of urinary system cancers: a systematic review and meta-analysis

  2021cites this paper
• Development and validation of a prediction model using molecular marker for long‐term survival in unresectable stage III non‐small cell lung cancer treated with chemoradiotherapy

  2021cites this paper
• Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumab.

  2021cites this paper
• The time-series behavior of systemic inflammation-immune status in predicting survival of locally advanced non-small cell lung cancer treated with chemoradiotherapy

  2021cites this paper
• Prognostic impact of elevated pre-treatment systemic immune-inflammation index (SII) in hepatocellular carcinoma

  2020cites this paper
• The Change of Systemic Immune-Inflammation Index Independently Predicts Survival of Colorectal Cancer Patients after Curative Resection

  2020cites this paper
• Chemotherapy-Induced Reduction of Neutrophil-to-Lymphocyte Ratio Is Associated With Better Survival in Pancreatic Adenocarcinoma: A Meta-Analysis

  2020cites this paper
• Characterization of Immune Checkpoint Inhibitor-Related Cardiotoxicity in Lung Cancer Patients From a Rural Setting

  2020cites this paper
• Association between bone marrow fluorodeoxyglucose uptake and recurrence after curative surgical resection in patients with T1-2N0M0 lung adenocarcinoma: a retrospective cohort study.

  2020cites this paper
• Controlling Nutritional Status (CONUT) Score is a Prognostic Marker in III-IV NSCLC Patients Receiving First-line Chemotherapy

  2020influential citation
• Systemic inflammation, TNM staging and survival in patients with lung cancer

  2020cites this paper
• Prognostic significance of the neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small-cell lung cancer

  2020cites this paper
• The Clinical Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Brain Metastases from Non–Small Cell Lung Cancer-Harboring EGFR Mutations

  2020cites this paper
• Pretreatment systemic inflammation response index (SIRI) is an independent predictor of survival in unresectable stage III non-small cell lung cancer treated with chemoradiotherapy: a two-center retrospective study

  2020cites this paper
• Bystander Effects and Unintended Consequences: Time to Include the Spleen in Radiation Therapy Planning

  2020cites this paper
• CMAR_A_250688 5659..5665

  2020cites this paper
• Dynamic evaluation of neutrophil-to-lymphocyte ratio as prognostic factor in stage III non-small cell lung cancer treated with chemoradiotherapy

  2020cites this paper
• Local and Systemic Inflammatory Markers as Prognostic and Predictive Markers In Locally Advanced Triple Negative Breast Cancer

  2020cites this paper
• The association between gut butyrate‐producing bacteria and non‐small‐cell lung cancer

  2020cites this paper
• Impact of Age on Inflammation-Based Scores among Patients Diagnosed with Stage III Non-Small Cell Lung Cancer

  2020cites this paper
• Association of Pre- and Posttreatment Neutrophil–Lymphocyte Ratio With Recurrence and Mortality in Locally Advanced Non-Small Cell Lung Cancer

  2020influential citation
• The post-treatment neutrophil-to-lymphocyte ratio and changes in this ratio predict survival after treatment of stage III non-small-cell lung cancer with conventionally fractionated radiotherapy.

  2020cites this paper
• The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors.

  2020cites this paper
• Systemic immune-inflammation index predicted overall survival and radiosensitivity in advanced non-small-cell lung cancer.

  2020cites this paper
• A meta-analysis of the impact of neutrophil-to-lymphocyte ratio on treatment outcomes after radiotherapy for solid tumors

  2019cites this paper
• Full Issue PDF

  2019cites this paper
• Utilization of combined PD-L1 expression and neutrophil-to-lymphocyte ratio prior to surgery as a prognostic factor in non-small cell lung cancer with brain metastasis

  2019cites this paper
• The prognostic value of platelet-lymphocyte ratio and neutrophil-lymphocyte ratio in the treatment response and survival of patients with peripheral T-cell lymphoma

  2019cites this paper
• OTT_A_225544 8779..8787

  2019cites this paper
• Neutrophil-To-Lymphocyte Ratio Predicted Long-Term Chemotherapy Benefits In Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer Patients Without Sensitive Mutations

  2019cites this paper
• Roles of DNA repair enzyme OGG1 in innate immunity and its significance for lung cancer

  2019cites this paper
• Prognostic value of neutrophil-to-lymphocyte ratio in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy

  2019cites this paper
• Systemic Inflammation-immune Status Predicts Survival in Stage III-N2 Non-small Cell Lung Cancer.

  2019cites this paper
• Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers

  2019cites this paper
• The Prognostic Value of the Pretreatment Neutrophil/Lymphocyte Ratio in Patients with Glioblastoma Multiforme Brain Tumors: A Retrospective Cohort Study of Patients Treated with Combined Modality Surgery, Radiation Therapy, and Temozolomide Chemotherapy

  2019cites this paper
• Interdisciplinary multimodality management of stage III nonsmall cell lung cancer

  2019cites this paper
• Prognostic value of delta inflammatory biomarker-based nomograms in patients with inoperable locally advanced NSCLC.

  2019cites this paper
• Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy

  2019cites this paper
• Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors

  2019cites this paper
• Integrative nomogram of CT imaging, clinical, and hematological features for survival prediction of patients with locally advanced non-small cell lung cancer

  2019cites this paper
• Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD‐1 Axis Inhibitors in Patients With Advanced Non–Small‐Cell Lung Cancer

  2018cites this paper
• The effects of carboplatin and etoposide on advanced small cell lung cancer and serum tumor markers in correlation with long-term survival rate.

  2018cites this paper
• The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.

  2018cites this paper
• Marriage predicts for survival in patients with stage III non–small-cell lung cancer

  2018cites this paper
• Baseline neutrophilia, derived neutrophil‐to‐lymphocyte ratio (dNLR), platelet‐to‐lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel

  2018cites this paper
• The impact of the neutrophil:lymphocyte ratio in response and survival of patients with de novo diffuse large B-cell lymphoma.

  2018cites this paper
• Post-treatment lymphocytopaenia, integral body dose and overall survival in lung cancer patients treated with radical radiotherapy.

  2017cites this paper
• Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer.

  2017cites this paper